TY - JOUR
T1 - Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system
AU - Hosein, Peter J.
AU - Echenique, Ana
AU - Loaiza-Bonilla, Arturo
AU - Froud, Tatiana
AU - Barbery, Katuzka
AU - Rocha Lima, Caio M.
AU - Yrizarry, Jose M.
AU - Narayanan, Govindarajan
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2014/8
Y1 - 2014/8
N2 - Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.
AB - Purpose To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials and Methods A retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival. Results Between March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae. Conclusions Percutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.
UR - http://www.scopus.com/inward/record.url?scp=84905271642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905271642&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2014.04.007
DO - 10.1016/j.jvir.2014.04.007
M3 - Article
C2 - 24861662
AN - SCOPUS:84905271642
VL - 25
SP - 1233-1239.e2
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
SN - 1051-0443
IS - 8
ER -